Literature DB >> 1353991

Effect of dexmedetomidine, an alpha 2-adrenergic agonist, in the isolated heart.

W E Flacke1, J W Flacke, K D Blow, D F McIntee, B C Bloor.   

Abstract

Dexmedetomidine (DM) was studied in the isolated dog heart in the form of a Starling heart-lung preparation, (HLP). Hearts were subjected to increased loading by (a) increasing cardiac output, and (b) increasing systemic resistance. Results are depicted by cardiac function curves, prepared by plotting left atrial pressure against either systemic cardiac output or mean arterial pressure. DM, given in divided doses up to 44 micrograms, had no effect on heart rate or cardiac function, nor did injection of 0.5 mg of atipamezole, a selective alpha 2-antagonist. Additional injections of very large doses of DM, up to 4,444 micrograms, caused an increase in heart rate and a leftward shift of the function curves, ie, positive chronotropic and inotropic effects. Plasma catecholamine levels increased markedly between the 444 micrograms and the 4,444 micrograms cumulative doses of DM. Administration of 1 mg of prazosin had no effect, but 1 mg of propranolol returned the rate to baseline and markedly shifted function curves to the right and depressed their slopes. Thus, whereas low doses (corresponding to between 1 and 30 micrograms/kg in intact animals) of DM, given acutely IV, have been shown to depress cardiac function in intact and denervated dogs, this effect is not due to a direct effect on the myocardium. High doses, far beyond doses maximally effective in intact animals and man, release catecholamines from cardiac stores. Plasma DM levels after low doses in the HLP were between 1 to 10 times those seen in intact animals and human volunteers after the usual doses given clinically for their central effects. Because DM caused no myocardial depressant effect in the isolated, blood-perfused canine HLP, decreases in cardiac function seen after this drug is given to intact and autonomically denervated dogs must be due to factor(s) other than a direct action on the myocardium.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1353991     DOI: 10.1016/1053-0770(92)90006-s

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  5 in total

1.  Acute hemodynamic changes after rapid intravenous bolus dosing of dexmedetomidine in pediatric heart transplant patients undergoing routine cardiac catheterization.

Authors:  E H Jooste; W T Muhly; J W Ibinson; T Suresh; D Damian; A Phadke; P Callahan; S Miller; B Feingold; S E Lichtenstein; J G Cain; C Chrysostomou; P J Davis
Journal:  Anesth Analg       Date:  2010-11-08       Impact factor: 5.108

2.  Assessment of dexmedetomidine effects on left ventricular function using pressure-volume loops in rats.

Authors:  Kyuho Lee; Hye Jeong Hwang; Ok Soo Kim; Young Jun Oh
Journal:  J Anesth       Date:  2016-11-05       Impact factor: 2.078

3.  Dexmedetomidine for patients undergoing diagnostic cardiac procedures: a noninferiority study.

Authors:  Nina Deutsch; Julia C Finkel; Karen Gold; Yao I Cheng; Michael C Slack; Joshua Kanter; Zenaide M N Quezado
Journal:  Pediatr Cardiol       Date:  2012-11-04       Impact factor: 1.655

4.  Effects of vatinoxan on cardiorespiratory function and gastrointestinal motility during constant-rate medetomidine infusion in standing horses.

Authors:  H Tapio; M R Raekallio; A Mykkänen; S Männikkö; M Scheinin; R C Bennett; O Vainio
Journal:  Equine Vet J       Date:  2019-03-14       Impact factor: 2.888

5.  Dexmedetomidine enhances tolerance to bupivacaine cardiotoxicity in the isolated rat hearts: alpha 2 adrenoceptors were not involved.

Authors:  Fangfang Xia; Zhousheng Jin; Tingting Lin; Xixi Cai; Linmin Pan; Shi Wang; Yaoyao Cai; Hongfei Chen
Journal:  BMC Pharmacol Toxicol       Date:  2019-11-21       Impact factor: 2.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.